Skip to main content
International Journal of Bipolar Disorders

Table 1 Patient demographic characteristics of completer population at baseline (N = 280)

From: The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial

 

Lurasidone 20–60 mg/day (N = 90)

Lurasidone 80–120 mg/day (N = 96)

Placebo (N = 94)

Age, mean (SD)

41.2 (12.9)

41.7 (12.6)

39.1 (11.4)

Male, n (%)

43 (47.8 %)

41 (42.7 %)

44 (46.8 %)

White, n (%)

60 (66.7 %)

62 (64.6 %)

62 (66.0 %)

SDS total score, mean (SD)

10.1 (7.3)

10.0 (7.4)

13.3 (8.3)

MADRS total score, mean (SD)

29.9 (4.7)

29.7 (4.8)

29.8 (4.7)

HAM-A total score, mean (SD)

16.2 (6.6)

14.9 (4.9)

15.6 (6.1)

Q-LES-Q SF total score, mean (SD)

33.4 (13.8)

34.6 (12.8)

36.5 (13.2)

QIDS-SR16 total score, mean (SD)

14.0 (3.7)

14.3 (3.1)

14.5 (3.2)

Back to article page